Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nL-TARDB-006 in ALS due to TARDBP mutation
NCT07743268Phase 2Enrolling by invitation
- Sponsor
- n-Lorem Foundation
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nL-TARDB-006 in amyotrophic lateral sclerosis (ALS), sponsored by n-Lorem Foundation. Primary endpoints: Clinical Functioning at 12 months, Survival at 12 months and 1 more. Started Feb 2026; status: enrolling by invitation.
02
Drugs
nL-TARDB-006
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07743268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743268.